Merck KGaA Acquires Bio-Techne in a major consolidation within the life sciences sector, establishing a definitive agreement to purchase the Minneapolis-based provider of life science tools for US$73 per share in cash. This transaction equates to an enterprise value of approximately US$11.3 billion (EUR 9.9 billion), representing a substantial 36% premium over Bio-Techne’s one-month volume-weighted average trading price. The acquisition targets high-growth, next-generation markets, strengthening the combined entity’s position across the entire life science value chain from initial discovery through commercial manufacturing. Investors can track related market updates on the NASDAQ Exchange.
The integration leverages highly complementary portfolios to serve laboratory clients and biopharmaceutical manufacturers navigating increasingly complex workflows. Merck intends to utilize its global scale, manufacturing excellence, and established infrastructure to unlock broader geographic and omnichannel access for Bio-Techne’s specialized offerings. This alignment directly advances the long-term strategic agenda of the Merck Group to prioritize high-growth value drivers and platformed capabilities through disciplined M&A.
Leadership from both organizations emphasized the operational and strategic benefits for stakeholders, customers, and global workforces. Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck, noted that Bio-Techne represents an outstanding strategic fit that bridges critical product lines from research labs to production suites. Kim Kelderman, President and CEO of Bio-Techne, stated that the transaction validates the enduring value built by their team over 50 years and provides the necessary scale to deepen their scientific impact globally.
Financial Implications and Synergy Timelines as Merck Acquires Bio-Techne
Financially, the planned transaction is structured to be immediately accretive to sales growth and EBITDA pre-margin for both the Life Science business unit and the overall Merck Group post-closing. Senior management expects the transaction to become EPS pre-accretive by the third year following the official closing date. Furthermore, Merck projects annualized cost synergies of approximately EUR 140 million, which are anticipated to be fully realized by year 3 after closing, backed by a disciplined integration roadmap that maintains business continuity.
The technological assets acquired will significantly expand Merck’s existing Discovery Solutions, Advanced Solutions, and Process Solutions divisions. Bio-Techne brings a robust portfolio of recombinant proteins, cytokines, antibodies, and immunoassay kits alongside its ProteinSimple automated protein detection instruments and RNAscope spatial biology technologies. Furthermore, the transaction includes Bio-Techne’s 19.9% stake in Wilson Wolf Corporation, a manufacturer of G-Rex cell culture devices, with a forward contract structured to acquire full ownership immediately after calendar year 2027. Technical specifications regarding these reagents and workflows are accessible via the Bio-Techne Portal.
From an organizational standpoint, the combination unites two large-scale workforces across North America, Europe, and the Asia-Pacific region. Bio-Techne brings over 3,000 global employees across 34 locations and 15 manufacturing facilities into Merck’s network, which already features 14,000 employees in the United States alone. This expansion builds upon Merck’s historic US$35 billion inorganic investments in the U.S., which includes the integrations of Millipore in 2010, Sigma-Aldrich in 2015, Versum in 2019, and SpringWorks Therapeutics in 2025.
Execution Parameters, Funding Mechanics, and Advisors for the Merger
To fund the US$11.3 billion enterprise value transaction, Merck will utilize a balanced combination of existing cash on hand and proceeds generated from new debt issuance. The corporate financial strategy explicitly guarantees the preservation of Merck’s strong investment-grade credit rating. The merger agreement has received formal approval from Bio-Techne’s Board of Directors and Merck’s internal corporate bodies, with the definitive closing projected for late 2026 or early 2027, pending shareholder and regulatory approvals. Transaction advisory services are being provided by Guggenheim Securities and J.P. Morgan.
Transaction Core Valuation parameters
| Metric Specification | Value Metric Data |
| Target Entity | Bio-Techne Corporation (NASDAQ: TECH) |
| Acquiring Entity | Merck KGaA |
| Per Share Purchase Value | US$73.00 (All-Cash Structure) |
| Enterprise Value (USD) | US$11.3 Billion |
| Enterprise Value (EUR) | EUR 9.9 Billion |
| Trading Premium Baseline | 36% over 1-month volume weighted average price |
| Lead Transaction Advisors | Guggenheim Securities, J.P. Morgan |
| Target Closing Window | Late 2026 to Early 2027 |
Projected Financial Synergies and Accretion Target Timelines
| Milestone Type | Expected Financial Outcome |
| Immediate Post-Closing Accretion | Positive impact on Sales Growth & EBITDA pre margin |
| EPS Pre Accretion Target | Fully accretive by Year 3 post-closing |
| Annualized Cost Synergies | Approximately EUR 140 Million |
| Synergy Realization Target | 100% integration realization by Year 3 post-closing |
| Funding Strategy Profile | Combined Cash on Hand and New Debt Issuance |
| Corporate Credit Mandate | Preservation of a strong investment-grade credit rating |
Bio-Techne Operational Asset Profile
| Asset Category | Reported Metrics (FY2025 Baseline) |
| Annual Net Sales | > US$1.2 Billion (Fiscal Year 2025) |
| Total Global Headcount | More than 3,000 employees |
| U.S. Headcount Concentration | Approximately 2,300 employees |
| Global Operational Footprint | 34 distinct locations |
| Manufacturing Infrastructure | 15 facilities (U.S., Canada, UK, Switzerland, China) |
| Core Workflow Technologies | ProteinSimple instruments, RNAscope hybridization tools |
| Wilson Wolf Equity Position | 19.9% stake (100% forward contract execution post-calendar 2027) |
Chronological History of Merck M&A Investments in the United States
| Acquisition Year | Acquired Target Entity | Primary Strategic Workflow Focus | Total Portfolio Capitalization |
| 2010 | Millipore | Filtration & Bioprocess Infrastructure | Part of cumulative US$35 Billion pool |
| 2015 | Sigma-Aldrich | Reagents, Chemicals, Lab Consumables | Part of cumulative US$35 Billion pool |
| 2019 | Versum | Advanced Electronics & Semiconductors | Part of cumulative US$35 Billion pool |
| 2025 | SpringWorks Therapeutics | Advanced Therapeutics Portfolio expansion | Part of cumulative US$35 Billion pool |
| 2026/2027 | Bio-Techne Corporation | Multi-omics, Spatial Biology, Proteomics | US$11.3 Billion Enterprise Value |
